Actinium Pharmaceuticals (ATNM) Stock Statistics & Valuation Metrics

Actinium Pharmaceuticals has a market cap or net worth of $24.22M. The enterprise value is -$8.61M.

Actinium Pharmaceuticals has 31,441,437 shares outstanding. The number of shares has decreased by -2.65% in one year.

Actinium Pharmaceuticals’s return on equity (ROE) is -4.33 and return on invested capital (ROIC) is -81.40%.

The current PE Ratio of Actinium Pharmaceuticals is 2.2. Actinium Pharmaceuticals’s PEG ratio is 0.09.

In the last 12 months, Actinium Pharmaceuticals had revenue of 90.00K and earned -33.89M in profits. Earnings per share was -1.09.

In the last 12 months, operating cash flow was -22.66M and capital expenditures -584.00K, giving a free cash flow of -23.25M billion.

Actinium Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Actinium Pharmaceuticals upcoming earnings date is Nov 23, 2026, TBA (Confirmed).

Actinium Pharmaceuticals as a current ratio of 6.20, with Debt / Equity ratio of 4.43%

In the past 12 months, Actinium Pharmaceuticals has paid 0.00 in taxes.

Actinium Pharmaceuticals EV to EBITDA ratio is 0.12, with an EV/FCF ratio of 0.16.

Actinium Pharmaceuticals has $36.47M in cash and marketable securities with $1.34M in debt, giving a net cash position of $35.13M billion.

Gross margin is 101.13%, with operating margin of -40274.44%, and net profit margin of -37652.22%.

The average price target for Actinium Pharmaceuticals is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy